This was quite a week in biotechnology. You had a major premium buyout and had much data come out from the American Society of Clinical Oncology (ASCO) and others. This is far from all of the movers, but it is a brief summary of the major gainers from BioHealthInvestor.com showing how large some moves were in biotechnology this week.

Acorda Therapeutics Inc. (NASDAQ: ACOR) had a great week after it announced positive data from a second Phase III study of its Fampridine-SR for patients' walking abilities who suffer from multiple sclerosis (MS). FULL DETAILS

Auxilium Pharmaceuticals Inc. (NASDAQ: AUXL) was a strange stock this week. The company reported great news but shares slid before the market figured out it had misinterpreted news in the company. INITIAL DETAILS

Inspire Pharmaceuticals Inc. (NASDAQ: ISPH) saw a surge after it reached its primary endpoint in Phase III trial of Denufosol for Cystic Fibrosis. FULL DETAILS

Monday, December 31

• PDUFA date for Pharmacyclics (NASDAQ: PCYC)' Xcytrin for treatment of non-small cell lung cancer patients with brain metastases.

Tuesday, January 1

• Markets closed for New Year's holiday.

Wednesday, January 2

• PDUFA date for SkyePharmaceuticals (OTC: SKYEY) and Sciele Pharmaceuticals (NASDAQ: SCRX) Sular Formulation for Hypertension. The FDA extended the PDUFA Date from November 2, 2007.

Thursday, January 3

• Ford Motor Company (NYSE: F) to report monthly sales at 1pm
• General Motors (NYSE: GM) to report monthly sales at 2pm.
• AngioDynamics (NASDAQ: ANGO) to report Q2 earnings; conference call at 4:30pm.

Friday, January 4

• Millennium Pharmaceuticals (NASDAQ: MLNM) to provide guidance at 8am.
• Checkpoint Systems (NYSE: CKP) to provide guidance at 10am.
• Federal Reserve Govenor Kohn to provide keynote speech at the AEA Annual Meeting in New Orleans at 11:45am.